Antibiotic Prescribing for Acute Bronchitis: How Low Can We Go?

By the time I graduated from medical school in 1975, I had learned that most respiratory tract infections in otherwise healthy children and adults were caused by viruses, such as parainfluenza, influenza, adenovirus, and respiratory syncytial virus. This learning was reinforced during my family practice residency training in Charleston, SC. I was taught that the challenge of primary care practice is to distinguish the many patients with benign, self-limited respiratory tract infections from those patients who are more seriously ill with bacterial pneumonia and who need an antibiotic to recover more quickly and more certainly. Armed with this scientific knowledge, I marched valiantly into practice, determined to base my prescribing on good science. It was only in rural practice that I clearly recall regularly confronting syndromes called “acute bronchitis” and “sinusitis,” for which patients seemed to expect an antibiotic and for which their previous physicians had prescribed one. “I get this bronchitis every fall. Dr. Smith gives me a shot of penicillin and I’m fine 2 days later.” With modest success I was able to talk patients out of this approach, but I more frequently failed than succeeded, though many were willing to take my prescription for pills as an acceptable alternative to the shot in the buttoc.

A quarter-century later I am still fighting the good battle of appropriate antibiotic use for respiratory tract infections. After a 25-year cold war, however, the battle is heating up! The Centers for Disease Control and Prevention has entered the fray, urging us and our patients to use antibiotics sparingly and wisely for acute respiratory tract infections.

The study was, however, underpowered to detect antibiotic prescribing-no resistant patients were described, and no other initiatives were effective. The investigators nearly came up empty handed. Patients’ signs and symptoms were poor predictors of antibiotic use. Why? To answer this question, Hueston et al4 in this issue of the JABFP suggests that, for patients with the diagnosis of acute bronchitis, the answer might not be 0%. After the successful campaign to reduce antibiotic use for acute bronchitis by Ornstein et al,5 a stubborn residual of 26% of patients received an antibiotic. Why? To answer this question, Hueston et al4 in this issue of the JABFP suggests that, for patients with the diagnosis of acute bronchitis, the answer might not be 0%.

These and other initiatives show that it is possible to reduce use of antibiotics for acute respiratory tract infections, but how low can we go? The report by Hueston et al4 in this issue of the JABFP suggests that, for patients with the diagnosis of acute bronchitis, the answer might not be 0%. After the successful campaign to reduce antibiotic use for acute bronchitis by Ornstein et al,5 a stubborn residual of 26% of patients received an antibiotic. Why? To answer this question, Hueston et al4 in this issue of the JABFP suggests that, for patients with the diagnosis of acute bronchitis, the answer might not be 0%.

Children were much less likely to receive an antibiotic than adults, 3% compared with 34%. Patient expectation could not be measured in this...
study, but it is a likely explanation for this striking difference. Perhaps parents are more willing to take a watch-and-wait approach for their children because the current national antiantibiotic campaign has begun to have some effect, whereas adults who might have received an antibiotic for a similar infection in the past are more likely to demand an antibiotic. Recently, Dosh and colleagues found that patient demand for an antibiotic for an upper respiratory tract infection, acute bronchitis, and acute sinusitis was strongly predicted by having received an antibiotic for a previous similar illness.

I doubt that patient expectation is the only factor driving continued antibiotic prescribing for acute bronchitis as well as other common acute respiratory tract infections, or ARIs. (I prefer this terminology rather than the anatomic nomenclature of bronchitis, sinusitis, and upper respiratory tract infection, because the same organism might cause acute bronchitis in one person, simple upper respiratory tract infection in another, and acute sinusitis in yet another.) Based on my many discussions with family physicians and from our own research, physicians do believe that some patients with ARIs benefit from antibiotic treatment. In a prospective descriptive study of diagnosis and treatment of ARIs in a rural primary care research network, we found a typical pattern of antibiotic prescribing: 21% for upper respiratory tract infections, 80% for acute bronchitis, and 98% for acute sinusitis. In this “untrained” group of physicians and patients, antibiotic prescribing was not independently predicted by any symptoms but was predicted by a small number of physical findings: discolored nasal discharge, rales or rhonchi, sinus tenderness, and postnasal drainage. Surprisingly, patient expectation was not an independent predictor of antibiotic prescribing.

Hueston and colleagues speculate that factors other than signs, symptoms, and clinician characteristics predict antibiotic prescribing for acute bronchitis. I agree. In our study of ARIs, we explored this issue by asking clinicians the following question for each patient for whom an antibiotic was prescribed: Other than the diagnosis, what other factors did you consider when prescribing an antibiotic for this patient? Clinicians reported other factors in 95% of cases. The most common reasons were patient not improving (21%), patient getting worse (19%), and patient has been sick for too long (19%). Clinicians prescribed an antibiotic in 98% of cases in which they believed the likelihood of an adverse outcome was high if no antibiotic was prescribed.

How low can we go with antibiotic prescribing for acute respiratory infections? Here are my targets for the year 2005: upper respiratory tract infections 10%; acute bronchitis 25%; acute sinusitis 50%. Until the prognostic uncertainty of prolonged symptoms is resolved (or not!) by a large randomized clinical trial, many physicians will continue to reach for the prescription pad for patients who have acute respiratory tract infections who have been sick for too long or who are not getting better.

John M. Hickner, MD, MS
East Lansing, Mich

References